TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics” is pleased to announce that it has confirmed a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) for the first quarter of calendar year 2022. This program milestone brings the…


Previous articleEditor’s Choice Award 2021-Best Study on Psychedelics and Nature
Next articleMindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System